Illumina, Inc. (ILMN) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $165.97 (-0.55%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 6, 2026 | Catherine Ramsey Schulte | Robert W. Baird | $137.00 | -17.5% |
| Jan 26, 2026 | Subbu Nambi | Guggenheim | $170.00 | +2.4% |
| Jan 20, 2026 | Daniel Arias | Stifel Nicolaus | $155.00 | -6.6% |
| Jan 5, 2026 | Vijay Kumar | Evercore ISI | $155.00 | -6.6% |
| Oct 31, 2025 | Vijay Kumar | Evercore ISI | $142.00 | -14.4% |
| Oct 31, 2025 | Luke Sergott | Barclays | $100.00 | -39.7% |
| Jun 24, 2025 | Luke Sergott | Barclays | $85.00 | -48.8% |
| May 15, 2025 | David Westenberg | Piper Sandler | $185.00 | +11.5% |
| Feb 3, 2025 | Luke Sergott | Barclays | $130.00 | -21.7% |
| Jan 10, 2025 | Eve Burstein | Bernstein | $140.00 | -15.6% |
| Jan 2, 2025 | Vijay Kumar | Evercore ISI | $180.00 | +8.5% |
| Nov 6, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $139.00 | -16.3% |
| Nov 5, 2024 | Kyle Mikson | Canaccord Genuity | $145.00 | -12.6% |
| Nov 5, 2024 | Luke Sergott | Barclays | $145.00 | -12.6% |
| Oct 17, 2024 | Shubhangi Gupta | HSBC | $180.00 | +8.5% |
| Aug 28, 2024 | Jasper Hellweg | Argus Research | $150.00 | -9.6% |
| Aug 16, 2024 | Narumi Nakagiri | Daiwa | $154.00 | -7.2% |
| Aug 15, 2024 | Sung Ji Nam | Scotiabank | $164.00 | -1.2% |
| Aug 14, 2024 | Nick Setyan | Wedbush | $58.00 | -65.1% |
| Aug 14, 2024 | Luke Sergott | Barclays | $125.00 | -24.7% |
Top Analysts Covering ILMN
ILMN vs Sector & Market
| Metric | ILMN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.73 | 2.24 | 2.41 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | -6.3% | +11475.0% | +17.1% |
| P/E Ratio | 30.35 | 4.00 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-28 | $4.51B | $4.54B | $4.58B | 12 |
| 2027-03-28 | $1.11B | $1.13B | $1.15B | 6 |
| 2027-06-28 | $1.14B | $1.17B | $1.19B | 4 |
| 2027-09-28 | $1.18B | $1.20B | $1.23B | 4 |
| 2027-12-28 | $1.25B | $1.27B | $1.29B | 6 |
| 2028-03-28 | $1.18B | $1.20B | $1.22B | 6 |
| 2028-06-28 | $1.22B | $1.24B | $1.26B | 3 |
| 2028-09-28 | $1.26B | $1.29B | $1.31B | 3 |
| 2028-12-28 | $1.36B | $1.39B | $1.41B | 6 |
| 2029-12-28 | $5.33B | $5.40B | $5.47B | 8 |
| 2030-12-28 | $5.61B | $5.68B | $5.76B | 8 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-28 | $5.08 | $5.12 | $5.16 | 10 |
| 2027-03-28 | $1.25 | $1.29 | $1.32 | 7 |
| 2027-06-28 | $1.39 | $1.43 | $1.46 | 7 |
| 2027-09-28 | $1.49 | $1.53 | $1.56 | 7 |
| 2027-12-28 | $1.59 | $1.63 | $1.67 | 7 |
| 2028-03-28 | $1.40 | $1.44 | $1.47 | 8 |
| 2028-06-28 | $1.62 | $1.67 | $1.71 | 8 |
| 2028-09-28 | $1.76 | $1.81 | $1.86 | 8 |
| 2028-12-28 | $1.87 | $1.92 | $1.96 | 8 |
| 2029-12-28 | $7.40 | $7.53 | $7.65 | 2 |
| 2030-12-28 | $8.09 | $8.23 | $8.36 | 2 |
Frequently Asked Questions
What is the analyst consensus for ILMN?
The consensus among 15 analysts covering Illumina, Inc. (ILMN) is Hold with an average price target of $147.13.
What is the highest price target for ILMN?
The highest price target for ILMN is $562.00, set by Dan Brennan at Cowen & Co. on 2022-02-14.
What is the lowest price target for ILMN?
The lowest price target for ILMN is $58.00, set by Nick Setyan at Wedbush on 2024-08-14.
How many analysts cover ILMN?
15 analysts have issued ratings for Illumina, Inc. in the past 12 months.
Is ILMN a buy or sell right now?
Based on 15 analyst ratings, ILMN has a consensus rating of Hold (2.73/5) with a -6.3% upside to the consensus target of $147.13.
What are the earnings estimates for ILMN?
Analysts estimate ILMN will report EPS of $5.12 for the period ending 2026-12-28, with revenue estimated at $4.54B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.